# TPN-101 in Aicardi-Goutières Syndrome (AGS)

> **NCT05613868** · PHASE2 · TERMINATED · sponsor: **Transposon Therapeutics, Inc.** · enrollment: 4 (actual)

## Conditions studied

- Aicardi-Goutières Syndrome (AGS)

## Interventions

- **DRUG:** TPN-101

## Key facts

- **NCT ID:** NCT05613868
- **Lead sponsor:** Transposon Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-03-15
- **Primary completion:** 2025-02-27
- **Final completion:** 2025-02-27
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05613868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05613868, "TPN-101 in Aicardi-Goutières Syndrome (AGS)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05613868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*